MRI-Guided Neoadjuvant Chemo May Benefit Patients With HR-, HER2+ Breast Cancer
Early data suggest that using MRI to guide neoadjuvant chemotherapy may be beneficial for patients with stage II-III, HR-, HER2+ breast cancer.
Early data suggest that using MRI to guide neoadjuvant chemotherapy may be beneficial for patients with stage II-III, HR-, HER2+ breast cancer.
The goal of screening for breast cancer is to find it early, before it has spread to lymph nodes, to reduce breast cancer mortality and…
Nurse insights from the MajesTEC-1 trial and a survey of nurses was used to identify management options for CRS in this patient population.
The NCCR*Explorer is an interactive data investigation tool from the NCI that leverages data from NCCR registries. It provides incidence and survival statistics for cancers…
On April 29, the FDA granted traditional approval to tisotumab vedotin-tftv (Tivdak) for patients with recurrent or metastatic cervical cancer whose disease progressed on or…
Likely more than 1 million people in Colorado have some form of medical debt. These seven charts explain how much they owe and where they…
The FDA issued a ‘safe to proceed’ for the investigational new drug application for PRAME TCR/IL-15 NK for relapsed or refractory myeloid malignancies.
ATLANTA, April 30, 2024— The American Cancer Society (ACS) commends today’s updated recommendations for breast cancer screening from the United States Preventive Services Task Force…
In this JAMA Patient Page, the US Preventive Services Task Force provides a guide to screening for breast cancer.
During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed the intracranial efficacy of brigatinib from the ALTA-1L trial for patients with ALK+ non–small cell…